Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma

PHASE3CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

December 31, 1998

Primary Completion Date

December 31, 2001

Study Completion Date

December 31, 2001

Conditions
Systemic Sclerosis
Interventions
DRUG

Relaxin

10 ug/kg/day or 25 ug/kg/day

DRUG

Relaxin

Placebo

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

collaborator

Boston University

OTHER

collaborator

University of Chicago

OTHER

collaborator

UConn Health

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

Medical University of South Carolina

OTHER

collaborator

Stanford University

OTHER

collaborator

Georgetown University

OTHER

collaborator

University of California, San Diego

OTHER

collaborator

Wayne State University

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

Medical College of Wisconsin

OTHER

lead

University of Medicine and Dentistry of New Jersey

OTHER

NCT00704665 - Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma | Biotech Hunter | Biotech Hunter